Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.

Literature DB >> 11600393

In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.

H Okamoto¹, S Miyazaki, K Tateda, Y Ishii, K Yamaguchi.

Abstract

The in vivo activity of telithromycin against erythromycin A- and penicillin G-resistant Streptococcus pneumoniae was superior to that of azithromycin, clarithromycin, cefdinir, and levofloxacin. In respiratory tract infections caused by erythromycin A-susceptible S. pneumoniae or Haemophilus influenzae in mice, telithromycin was more effective than clarithromycin and comparable to azithromycin.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2001 PMID： 11600393 PMCID： PMC90819 DOI： 10.1128/AAC.45.11.3250-3252.2001

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

9 in total

1. In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models.

Authors: A Bonnefoy; M Guitton; C Delachaume; P Le Priol; A M Girard
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

2. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.

Authors: S Yoshizumi; H Domon; S Miyazaki; K Yamaguchi
Journal: Antimicrob Agents Chemother Date: 1998-04 Impact factor: 5.191

3. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors: K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal: Antimicrob Agents Chemother Date: 1996-06 Impact factor: 5.191

4. Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics.

Authors: A Bonnefoy; P Le Priol
Journal: J Antimicrob Chemother Date: 2001-04 Impact factor: 5.790

5. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

Authors: K Yamaguchi; H Domon; S Miyazaki; K Tateda; A Ohno; K Ishii; T Matsumoto; N Furuya
Journal: Antimicrob Agents Chemother Date: 1998-03 Impact factor: 5.191

6. New murine model of bronchopneumonia due to cell-bound Haemophilus influenzae.

Authors: S Miyazaki; T Nunoya; T Matsumoto; K Tateda; K Yamaguchi
Journal: J Infect Dis Date: 1997-01 Impact factor: 5.226

7. Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.

Authors: H Okamoto; S Miyazaki; K Tateda; Y Ishii; K Yamaguchi
Journal: J Antimicrob Chemother Date: 2000-11 Impact factor: 5.790

8. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.

Authors: A L Barry; P C Fuchs; S D Brown
Journal: Antimicrob Agents Chemother Date: 1998-08 Impact factor: 5.191

9. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.

Authors: D J Biedenbach; M S Barrett; R N Jones
Journal: Diagn Microbiol Infect Dis Date: 1998-06 Impact factor: 2.803

9 in total

4 in total

1. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Authors: Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191